Modified dendritic cell-derived exosomes activate both NK cells and T cells through the NKG2D/NKG2D-L pathway to kill CML cells with or without T315I mutation

BACKGROUND: Tyrosine kinase inhibitors have achieved quite spectacular advances in the treatment of chronic myeloid leukemia (CML), but disease progression and drug resistance that related to the T315I mutation, remain major obstacles. Dendritic cell-derived exosomes (Dex) induce NK cell immunity, b...

Descripción completa

Detalles Bibliográficos
Autores principales: Du, Zhuanyun, Huang, Zhenglan, Chen, Xi, Jiang, Guoyun, Peng, Yuhang, Feng, Wenli, Huang, Ningshu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9172178/
https://www.ncbi.nlm.nih.gov/pubmed/35672796
http://dx.doi.org/10.1186/s40164-022-00289-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9172178/
https://www.ncbi.nlm.nih.gov/pubmed/35672796
http://dx.doi.org/10.1186/s40164-022-00289-8

Ejemplares similares